Updated:
Leerink Partners
Leerink Partners is a healthcare-focused investment bank and asset manager founded by Jeffrey Leerink in 1995, serving institutions and family offices.
Leerink Partners
Jeffrey Leerink launched the firm in 1995 after a career at Lehman Brothers, positioning it initially as a boutique healthcare investment bank. The firm built its reputation by advising and financing biopharmaceutical and medical technology companies, and later added an asset management arm. It operates primarily from Boston, with additional offices in New York and San Francisco. The firm's strategy centers on deep sector specialization in healthcare. It offers advisory, equity capital markets, and asset management services. The asset management business invests in public and private securities, focusing on biotechnology, pharmaceuticals, and life sciences tools. Leerink Partners has underwritten IPOs for companies including Alnylam Pharmaceuticals (per SEC filings, 2004) and Sage Therapeutics (per SEC filings, 2014), and advised on strategic mergers such as the acquisition of ARIAD Pharmaceuticals by Takeda (per public announcement, 2017). The firm operates as both an investment bank and an asset manager. It is a registered broker-dealer and a registered investment adviser. The asset management team manages separate accounts and pooled vehicles for institutional investors, family offices, and high-net-worth individuals. Leerink Partners does not publicly disclose its assets under management or team size. As of 2024, the firm remains independent, with no disclosed plans for succession or ownership changes. A structural differentiator is the firm's complete integration of investment banking and asset management within a single healthcare-focused platform. This allows the asset management team to leverage proprietary research and deal flow from the banking side, while maintaining compliance walls. The model is rare among healthcare boutiques, most of which keep these businesses separate.
General information
Firm type
Asset Manager
Year founded
1995
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Additional offices
New York, NY, United States · San Francisco, CA, United States
Principals
Jeffrey A. Leerink
Chief Executive Officer
Sector focus
Frequently asked questions
Who leads investment decisions at Leerink Partners?
Jeffrey A. Leerink serves as CEO and oversees the firm's strategic direction. The asset management arm is led by a team of portfolio managers with expertise in healthcare and life sciences investing. Specific names of investment committee members are not publicly disclosed.
How does Leerink Partners source deals and generate returns?
The firm leverages its healthcare investment banking platform, which provides proprietary access to private and public companies across biotechnology, pharmaceuticals, and medical technology. The asset management team uses fundamental research and in-house sector expertise to identify investment opportunities, often participating in healthcare IPOs and follow-on offerings the bank underwrites.
What investment stages and asset classes does Leerink Partners focus on?
Leerink Partners invests primarily in public equities and private securities within the healthcare sector. It targets growth-stage companies, including pre-commercial biotech firms and later-stage public companies. The firm also manages cash and fixed-income allocations as part of its asset management mandates.
Is Leerink Partners a single-family office or independent asset manager?
Leerink Partners is an independent, registered investment adviser and broker-dealer, not a single-family office. It manages assets for a diversified client base that includes institutional investors, family offices, foundations, and high-net-worth individuals.
Does Leerink Partners engage in co-investments alongside external partners?
Yes, the firm participates in syndicated investments and co-investments, particularly in healthcare private placements and IPOs. It collaborates with other healthcare-focused institutional investors and family offices, though specific co-investment partners are not publicly named.
What are Leerink Partners' known portfolio holdings or investments?
Public filings indicate Leerink Partners has underwritten offerings for Alnylam Pharmaceuticals, Sage Therapeutics, and ARIAD Pharmaceuticals. Its asset management portfolios contain holdings across major healthcare indices and individual names, but specific positions are not disclosed regularly.
How is Leerink Partners structured as a firm—separate entities or integrated?
Leerink Partners operates as a single integrated company with an investment banking division and an asset management division. Compliance walls separate the two. The firm is registered as a broker-dealer with FINRA and as an investment adviser with the SEC. It has no publicly disclosed parent or holding company.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: